Abdel-Rahman WM. 2008. Genomic instability and carcinogenesis: an update. Curr Genomics 9: 535-541.
Bartek J, Lukas J. 2003. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer cell 3: 421-429.
Carlessi L, Buscemi G. 2007. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 6: 935-944.
Carrassa L, Broggini M. 2004. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: Differential activity in cells expressing, or not, p53. Cell Cycle 3: 1175-1179.
Castedo M, Perfettini JL. 2004. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 23: 4353-4361.
Cliby WA, Roberts CJ. 1998. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J 17: 159-169.
Duong HQ, Hong YB. 2013. Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine. J Cell Mol Med 17: 1261-1270.
Gogineni V R, Nalla A K. 2011. Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells. Cancer Lett 313: 64-75.
Huang M, Miao ZH. 2008. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol Cancer Ther 7: 1440-1449.
Jobson A G, Lountos GT. 2009. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther 331: 816-826.
Karnitz L M, Flatten K S. 2005. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 68: 1636-1644.
Mir Mohammadrezaei F, Mohseni kouchesfehani M, Montazeri H, Gharghabi M, Ostad SM, Ghahremani MH. 2013. Signaling crosstalk of FHIT, CHK2 and p38 in etoposide induced growth inhibition in MCF-7 cells. Cell Signal 25: 126-132
Pabla N, Huang S. 2008. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 283: 6572-6583.
Perona R, Moncho-Amor V. 2008. Role of CHK2 in cancer development. Clin Transl Oncol 10: 538-542.
Saldivar JC, Bene J. 2012. Characterization of the role of Fhit in suppression of DNA damage. Adv Biol Regul 53: 77-85
Stevens C, Smith L. 2003. Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 5: 401-409.
Stolz A, Ertych N. 2011. Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability. Clin Cancer Res 17: 401-405.
Théard D, Coisy M. 2001. Etoposide and adriamycin but not genistein can activate the checkpoint kinase Chk2 independently of ATM/ATR. Biochem Biophys Res Commun 289: 1199-1204.
Yutori H, Semba S. 2008. Restoration of fragile histidine triad expression restores Chk2 activity in response to ionizing radiation in oral squamous cell carcinoma cells. Cancer Sci 99: 524-530.
Zhang P, Wang J. 2004. CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. Mol Cancer 3:3- 14.